Niche Market Target neonatal care suppliers and hospitals focusing on newborn respiratory support and opioid-exposed or preterm infant care, leveraging Prapela’s noninvasive stimulation therapy as a specialized product add-on to existing NICU equipment ecosystems.

Regulatory Advantage Leverage FDA Breakthrough Device Designation and ongoing clinical evaluation to position as a technologically advanced, cleared option for improving infant breathing and oxygenation, appealing to procurement teams seeking innovative, regulated solutions.

Funding Credibility Highlight sustained funding history and grant support in communications to potential health system partners, emphasizing validated research backing and long-term viability for scale in neonatal respiratory care.

Strategic Partnerships Explore collaborations with major medical device distributors and NICU integrators to expand reach beyond a small internal team, aligning with similar companies in the competitive landscape to accelerate adoption.

Lifecycle Expansion Position Prapela not only as a therapy but as a platform for neonatal respiratory optimization, considering future devices or services (e.g., caregiver education, remote monitoring) to broaden value proposition and upsell within hospital systems.